sars-cov-2 proteins and anti-covid-19 drugs block lytic reactivation of an oncogenic virus
sars-cov-2 proteins and anti-covid-19 drugs block lytic reactivation of an oncogenic virus
due to the mechanisms of sars-cov-2 infection to host cells and its pathogenesis remain largely unclear, there are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention.", "in the current study, we have reported that sars-cov-2 encoded proteins and some anti-covid-19 drugs currently used are able to induce lytic reactivation of kaposis sarcoma- associated herpesvirus (kshv), one of major human oncogenic viruses through manipulation of intracellular signaling pathways."


































)